We came across a bullish thesis on Agios Pharmaceuticals, Inc. on BioEquity Watch’s Substack. In this article, we will ...

U.S. commercial launch in thalassemia underway following December 2025 FDA approvalPre-sNDA meeting with FDA for mitapivat ...

Agios Pharmaceuticals’ pivot from cancer to rare diseases culminated in the $1.8 billion sale of its oncology business. But the biotech still needs capital to support a product launch and additional ...

Biopharma companies—including AstraZeneca, BioNTech and Agios—peered farther into the future on the second day of JPM, ...

Agios Pharmaceuticals has agreed to sell to Royalty Pharma rights to royalties on a brain cancer drug it invented and sold to Servier. Per deal terms announced Tuesday, Agios will receive $905 million ...

The average one-year price target for Agios Pharmaceuticals (NasdaqGS:AGIO) has been revised to $39.20 / share. This is an ...

Agios Pharmaceuticals will sell its rights to the 15% royalty it holds on potential U.S. net sales of vorasidenib to Royalty Pharma. Royalty Pharma announced this week that it will pay Agios $905 ...

Agios is a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. To learn more, visit and follow us on LinkedIn and X. Contacts: Investor Contact Morgan Sanford, Vice ...

After going it alone for the past 14 years, Agios is ready to find a dance partner to help move its pipeline forward. But as part of the hunt for a company or companies that may nod back to Agios’ ...

Cambridge, Massachusetts-based Agios will market its new product, a twice-daily tablet, under the name “Pyrukynd.” The FDA’s Thursday approval covers use of the drug in adults who have an inherited ...

Agios Pharmaceuticals Inc. has agreed to sell its oncology business to Boston’s Servier Pharmaceuticals in a deal worth up to $2 billion. Agios, of Cambridge, which has two cancer drugs on the market ...

On Thursday, Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced that the ACTIVATE-Kids Phase 3 study of mitapivat in children aged 1 to <18 years with PK deficiency who are not regularly transfused ...